Author

Neïla Benameur

Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation

2012 · Julien Haroche, Fleur Cohen-Aubart, et al. · Blood · 532

Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAFV600E-Mutated Erdheim-Chester Disease

2014 · Julien Haroche, Fleur Cohen-Aubart, et al. · Journal of Clinical Oncology · 288

Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine

2020 · Alexis Mathian, Matthieu Mahevas, et al. · Annals of the Rheumatic Diseases · 242

PDF

Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)

2017 · Fleur Cohen Aubart, Jean-François Emile, et al. · Blood · 211

Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib

2014 · Ahmed Idbaih, Karima Mokhtari, et al. · Neurology · 88

Efficacy of the MEK inhibitor cobimetinib for wild‐type BRAF Erdheim‐Chester disease

2016 · Fleur Cohen Aubart, Jean‐François Emile, et al. · British Journal of Haematology · 75

PDF

Rituximab-associated Vasculitis Flare: Incidence, Predictors, and Outcome

2019 · Anne Claire Desbois, Lucie Biard, et al. · The Journal of Rheumatology · 33

PDF

Efficacy of infliximab in the treatment of Erdheim-Chester disease

2018 · Fleur Cohen-Aubart, Philippe Maksud, et al. · Annals of the Rheumatic Diseases · 30

Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease

2014 · Fleur Cohen-Aubart, Jean-François Emile, et al. · Neurology · 30

Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment

2019 · Quentin Riller, Camille Cotteret, et al. · Journal of Neurology · 26

Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation

2022 · Makoto Miyara, Melissa Saichi, et al. · Frontiers in Immunology · 21

Pre-COVID-19 humoral immunity to common coronaviruses does not confer cross-protection against SARS-CoV-2

2020 · Makoto Miyara, Delphine Sterlin, et al. · medRxiv · 16

PDF

Safety and effectiveness of transjugular renal biopsy for systemic lupus erythematosus and antiphospholipid antibody syndrome patients taking antithrombotics

2019 · Hubert Nielly, Alexis Mathian, et al. · Nephrology Dialysis Transplantation · 13

Achieving lupus low-disease activity and remission states under belimumab in refractory systemic lupus erythematosus: time and organ involvement matter

2019 · Nabiha Sbeih, Alexis Mathian, et al. · Annals of the Rheumatic Diseases · 12

PDF

Determination of plasma concentration of Belimumab by LC-MS/MS: Method development, validation, and clinical application

2023 · Clémence Marin, Gaëlle Noé, et al. · Journal of Pharmaceutical and Biomedical Analysis · 10

Acute Pancreatitis From Treatment With BRAF Inhibitors in Erdheim-Chester Disease

2020 · Gordon J. Ruan, Gaurav Goyal, et al. · Pancreas · 6

Immune Reconstitution Syndrome After Nivolumab for Progressive Multifocal Leukoencephalopathy

2020 · Julien Haroche, Fleur Cohen Aubart, et al. · Neurology Clinical Practice · 3

Response to: ‘Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease' by Campochiaro et al

2020 · Fleur Cohen-Aubart, Neila Benameur, et al. · Annals of the Rheumatic Diseases · 1

PDF

Efficacité et tolérance de la cladribine dans les histiocytoses non Langerhansiennes

2020 · Q. Riller, N. Benameur, et al. · La Revue de Médecine Interne

Auto-immunité dans les histiocytoses du groupe L : impact pronostique et modulation sous thérapie ciblée

2018 · A. Roeser, F. Cohen Aubart, et al. · La Revue de Médecine Interne

Rémission et faible activité clinique sous traitement par belimumab dans le lupus systémique actif malgré les traitements standards

2018 · N. Sbeih, A. Mathian, et al. · La Revue de Médecine Interne

Tolérance et efficacité d’un biosimilaire de l’infliximab dans les indications hors AMM : suivi prospectif d’une cohorte de patients en médecine interne (registre BIOSIM)

2016 · C. Cotteret, F. Cohen Aubart, et al. · La Revue de Médecine Interne

Sarcoïdose survenant sous traitement par inhibiteur de BRAF : description de 3 cas et revue systématique de la littérature

2016 · A. Amoura, F. Cohen Aubart, et al. · La Revue de Médecine Interne

Treatment of Erdheim-Chester disease patients with the MEK inhibitor cobimetinib.

2016 · Fleur Cohen-Aubart, Jean-François Emile, et al. · Journal of Clinical Oncology

Efficacité à moyen terme du vémurafénib dans la maladie d’Erdheim–Chester

2013 · F. Cohen Aubart, L. Arnaud, et al. · La Revue de Médecine Interne

Works count: 27

Citation count: 1,637

H-index: 13

I10-index: 15